Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 61,475 shares (grant or award)
  2. 4 Grant or award Director acquired 61,475 shares (grant or award)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Grant or award Director acquired 122,950 shares (grant or award)
  6. 4 Open-market sale Director sold 11,200 shares at $2.34 ($26,181)
  7. 4 Open-market buy Director bought 1,724,137 shares at $2.90 ($4,999,997)
  8. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 344,828 shares (grant or award)
  9. 4 Grant or award President and CEO acquired 344,828 shares (grant or award)
  10. 4 Shares withheld for taxes Chief Technical Officer gave up 17,360 shares (to pay taxes)
  11. 4 Shares withheld for taxes President and CEO gave up 53,393 shares (to pay taxes)
  12. 4 Open-market buy CHIEF FINANCIAL OFFICER bought 190 shares at $3.60 ($683)
  13. 4 Grant or award Chief Technical Officer acquired 96,600 shares (grant or award)
  14. 4 Grant or award SVP, General Counsel acquired 41,800 shares (grant or award)
  15. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 29,400 shares (grant or award)
  16. 4 Grant or award Director acquired 211,973 shares (grant or award)
  17. 4 Grant or award EVP of R&D acquired 140,000 shares (grant or award)
  18. 4 Grant or award President and CEO acquired 317,800 shares (grant or award)
  19. 4 Shares withheld for taxes EVP of R&D gave up 24,690 shares (to pay taxes)
  20. 4 Planned sale Director sold 18,640 shares at $2.70 ($50,317)

Page 4 of 14 · 275 filings